Keros Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 136
- Market Cap
- $1.7B
- Website
- http://www.kerostx.com
- Introduction
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Keros Therapeutics Inc.
- Target Recruit Count
- 74
- Registration Number
- 2024-516009-22-00
- Locations
- 🇨🇿
Fakultni Nemocnice Brno, Brno, Czechia
🇨🇿Institute Of Hematology And Blood Transfusion, Prague, Czechia
🇨🇿Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove, Czechia
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Biological: Dose A KER-012Biological: Dose B KER-012Biological: Dose C KER-012Biological: Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT05975905
- Locations
- 🇺🇸
TROPOS Study Site 111, Scottsdale, Arizona, United States
🇺🇸TROPOS Study Site 107, Tucson, Arizona, United States
🇺🇸Site PI TROPOS Study Site 104, Stanford, California, United States
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Keros Therapeutics, Inc.
- Registration Number
- NCT05927012
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇮🇱Hadassah University Medical Center, Jerusalem, Israel
🇮🇱Galilee Medical Center, Nahariya, Israel
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- Drug: KER-050 monotherapyDrug: KER-050 in combination with ruxolitinib
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05037760
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇦🇺Concord Hospital, Concord, New South Wales, Australia
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04419649
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Center, Tampa, Florida, United States